Placebo cream + Ketoconazole 2% cream (formulation F012) (Nizoral) + Ketoconazole 2% cream (formulation F126)
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Pedis
Conditions
Tinea Pedis
Trial Timeline
Jul 1, 2007 → Oct 1, 2008
NCT ID
NCT01110330About Placebo cream + Ketoconazole 2% cream (formulation F012) (Nizoral) + Ketoconazole 2% cream (formulation F126)
Placebo cream + Ketoconazole 2% cream (formulation F012) (Nizoral) + Ketoconazole 2% cream (formulation F126) is a phase 3 stage product being developed by Johnson & Johnson for Tinea Pedis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01110330. Target conditions include Tinea Pedis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01110330 | Phase 3 | Terminated |
Competing Products
20 competing products in Tinea Pedis